Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification
Nucleic Acids Research · 13.10.2023 · 51 (18) · 10059-10074
DOI: 10.1093/nar/gkad676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 08.09.2023. Verfasst von Jakob Haldrup und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus C, Denmark. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Ribonucleoproteins, Nanoparticles. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeck Foundation, Innovation Fund, Synoptik Foundation.
Abstract (Originalsprache)
Implementation of therapeutic in vivo gene editing using CRISPR/Cas relies on potent delivery of gene editing tools. Administration of ribonucleoprotein (RNP) complexes consisting of Cas protein and single guide RNA (sgRNA) offers short-lived editing activity and safety advantages over conventional viral and non-viral gene and RNA delivery approaches. By engineering lentivirus-derived nanoparticles (LVNPs) to facilitate RNP delivery, we demonstrate effective administration of SpCas9 as well as SpCas9-derived base and prime editors (BE/PE) leading to gene editing in recipient cells. Unique Gag/GagPol protein fusion strategies facilitate RNP packaging in LVNPs, and refinement of LVNP stoichiometry supports optimized LVNP yield and incorporation of therapeutic payload. We demonstrate near instantaneous target DNA cleavage and complete RNP turnover within 4 days. As a result, LVNPs provide high on-target DNA cleavage and lower levels of off-target cleavage activity compared to standard RNP nucleofection in cultured cells. LVNPs accommodate BE/sgRNA and PE/epegRNA RNPs leading to base editing with reduced bystander editing and prime editing without detectable indel formation. Notably, in the mouse eye, we provide the first proof-of-concept for LVNP-directed in vivo gene disruption. Our findings establish LVNPs as promising vehicles for delivery of RNPs facilitating donor-free base and prime editing without formation of double-stranded DNA breaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
- Department of Ophthalmology, Aarhus University Hospital, Aarhus N, Denmark.
ORCID-Profile: Jonas Holst Wolff, Anne Bruun Rovsing, Emil Aagaard Thomsen, Jacob Giehm Mikkelsen
Förderung
- Lundbeck Foundation
- Innovation Fund
- Synoptik Foundation
- Velux Foundation
Zitieren
APA
Haldrup, J., Andersen, S., Labial, A. R. L., Wolff, J. H., Frandsen, F. P., Skov, T. W., Rovsing, A. B., Nielsen, I., Jakobsen, T. S., Askou, A. L., Thomsen, M. K., Corydon, T. J., Thomsen, E. A., & Mikkelsen, J. G. (2023). Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Research, 51(18), 10059-10074. https://doi.org/10.1093/nar/gkad676
Vancouver
Haldrup J, Andersen S, Labial ARL, Wolff JH, Frandsen FP, Skov TW, et al. Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Research. 2023;51(18):10059-10074. doi:10.1093/nar/gkad676
BibTeX
@article{Haldrup2023,
author = {Haldrup, Jakob and Andersen, Sofie and Labial, Alexander Rafael LaVilla and Wolff, Jonas Holst and Frandsen, Frederik Plum and Skov, Thomas Wisbech and Rovsing, Anne Bruun and Nielsen, Ian and Jakobsen, Thomas Stax and Askou, Anne Louise and Thomsen, Martin K and Corydon, Thomas J and Thomsen, Emil Aagaard and Mikkelsen, Jacob Giehm},
title = {Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {18},
pages = {10059--10074},
doi = {10.1093/nar/gkad676}
}
EUVIMED